Establishment and Application of the Drug Use Evaluation Criteria on Recombinant Human Granulocyte-col-ony Stimulating Factor for Cancer Patients / 中国药房
China Pharmacy
; (12): 4050-4052,4053, 2016.
Article
in Zh
| WPRIM
| ID: wpr-605483
Responsible library:
WPRO
ABSTRACT
OBJECTIVE:To provide reference for rational use of recombinant human granulocyte-colony stimulating factor (rhG-CSF) in cancer patients. METHODS:Referring to the expert advice and guideline of clinical application of rhG-CSF at home and abroad,DUE criteria on rhG-CSF for cancer patients was established;questionnaire was designed,and the medical re-cords of rhG-CSF in a third grade class A hospital was evaluated. RESULTS:The DUE criterion on rhG-CSF for cancer patients included 3 parts,such as drug indications,the course of medication and medication results,14 items in total. Through the imple-mentation of DUE,retrospective evaluation of 220 medical records showed that the application of rhG-CSF was up to the stan-dard in respects of drug indications,no contraindication,routine blood test and drug interaction monitoring at least twice every week,there still was irrational phenomenon. CONCLUSIONS:The established DUE criterion on rhG-CSF for cancer patients is with the characteristics of definite content,target and paracticabilitg,which can provide reference for the work development of clinical pharmacists.
Full text:
1
Index:
WPRIM
Type of study:
Guideline
/
Qualitative_research
Language:
Zh
Journal:
China Pharmacy
Year:
2016
Type:
Article